Antibacterial Agents TRIZ Cases

Increasing brain IL-17a levels converts inflammatory responses into therapeutic benefits, addressing ineffective current treatments.

Paecilomycone derivatives inhibit bacterial quorum sensing, reducing biofilm formation and virulence factor production in resistant strains.

Intranasal polypeptide vaccine targets respiratory mucosa to overcome preexisting antibody interference and boost IFN-gamma secretion.

Novel Streptomyces compound treats resistant bacteria like MRSA and VRE.

A chemical synthesis method prepares structurally uniform core oligosaccharide antigens from glucose, galactose, and mannose building blocks.

Extreme pH buffers kill gram-negative bacteria to reduce bloodstream infections without compromising pharmaceutical stability.

Novel tricyclic compounds with specific structural linkers exhibit potent antibacterial activity against Gram-positive and Gram-negative pathogens.

A humanized monoclonal antibody binds PD-1 to block immune evasion signals.

A PCV2 vaccine reduces concomitant infections in pigs by administering an effective antigen amount.

Bifidobacterium longum AH1206 modulates local immune responses to reduce mucosal inflammation while maintaining systemic defense against pathogens.

LSALT peptide blocks leukocyte recruitment to reduce tumor burden in the liver and lungs while protecting against sepsis.

Monocyclic anilide spirolactam compounds block receptor-mediated actions of calcitonin gene-related peptide to treat migraine and cluster headache conditions.

Nanoparticle compositions bind inactivated pathogens to stimulate robust mucosal immunity, preventing initial pathogen colonization.

A multivalent immunogenic composition combines Staphylococcus aureus Type 5 and Type 8 capsular saccharides conjugated to carrier proteins.

Purified recombinant PA production reduces adverse reactions and simplifies immunization schedules.

C12-PRP lipopeptide mediates minocycline and rifampicin entry through the outer membrane barrier of multidrug-resistant Pseudomonas aeruginosa.

Chimpanzee adenoviral vectors evade preexisting immunity and reduce contamination risks in vaccine production.

Acidic ion exchangers and acyloxymethyl intermediates simplify product isolation, avoiding toxic substances while maintaining catalyst reuse.

Converting amorphous Compound A to a crystalline phase resolves stability and hygroscopicity contradictions for Gram-negative bacterial treatment.

Recombinant Lactobacillus expresses the CRAMP protein to stimulate cellular immune responses in the intestinal tract.

A vault-like particle carrier delivers immunogenic peptides to stimulate protective immunity.

Converting amorphous Ceftiofur sodium into a crystalline form resolves stability and purification contradictions through phase transitions.

Pegylated phospholipids prevent teixobactin gelation, maintaining antibacterial potency against resistant pathogens.

A 1-hexyl-5-(4-methoxyphenyl)-2,4-diphenyl-1H-imidazole compound synthesized via a one-pot four-component reaction using pyridinium hydrogen sulfate as a catalyst.

Nonomuraea sp. MJM5123 cyclic peptides resolve drug resistance contradictions by destroying MDR and XDR strains while maintaining low mammalian cytotoxicity.

Administering microbial glycosidases degrades heparan sulfate, blocking SARS-CoV-2 spike protein binding and preventing infection.

Manganese-based organic framework loads drugs via adsorption and emits intrinsic fluorescence for tracking.

Specific hinge region mutations increase bioactivity against resistant pathogens while maintaining protein structure stability.

Optimizing the pH to 5.4-5.65 stabilizes carbetocin at room temperature, eliminating refrigeration needs for tropical distribution.

Fungal treatment converts waste date pits into a degraded composition that prevents antibiotic resistance while maintaining animal weight gain.

Phage ΦCJ20 lyses ETEC bacteria without inducing drug resistance, offering a stable biological alternative to antibiotics.

Inactivated Japanese encephalitis virus particles serve as an adjuvant to increase antibody titers, allowing reduced antigen amounts in mixed vaccines.

Universal T-cell epitopes broaden serotype coverage in conjugate vaccines while reducing manufacturing complexity.

Dry syrup powder mixtures combine beta-lactam antibiotics with powdered sugar and colloidal silicon dioxide to enhance flowability.

Substituted quinoline derivatives inhibit bacterial growth by targeting the F1F0 ATP synthase enzyme.

Beta-lactam compounds inhibit carbapenemases and ESBL enzymes, restoring antibiotic efficacy against resistant bacteria while serving as diagnostic reagents.

Aminoguanidine polycondensation yields biocidal polymers with lower mammalian toxicity.

Fusion proteins merge endolysins with peptides to prevent Gram-positive cell wall regeneration and enhance killing capacity.

Aqueous polymerization of activated alpha-amino acid monomers produces grafted polylysine dendrimers with controlled molecular size.

Extracting specific butyrate-producing bacteria from fecal microbiota avoids FMT risks while suppressing pathogen proliferation.

Measuring IL22 and lipocalin-2 levels identifies patients responsive to IL23 antagonists.

A vaccine targets constitutively expressed ESAT6 and CFP10 antigens to induce polyfunctional T-cell responses in latently infected individuals.

Antibodies bind plasma kallikrein critical residues to inhibit enzyme activity, reducing inflammation while preserving coagulation function.